Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $62.50 Consensus PT from Analysts
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) has earned a consensus rating of “Buy” from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have issued a report on […]
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) has earned a consensus rating of “Buy” from the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have issued a report on […]
